Pfizer Inc. (NYSE:PFE) Shares Sold by Enterprise Financial Services Corp

Enterprise Financial Services Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,951 shares of the biopharmaceutical company’s stock after selling 4,232 shares during the period. Enterprise Financial Services Corp’s holdings in Pfizer were worth $529,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Finally, Noble Wealth Management PBC acquired a new position in shares of Pfizer in the 4th quarter valued at $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 1.8 %

Shares of NYSE PFE opened at $26.71 on Friday. The stock has a market cap of $151.35 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The business has a 50-day moving average price of $26.30 and a 200 day moving average price of $27.24.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. Pfizer’s dividend payout ratio is 121.99%.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.